Event Details Home Engineered with Purpose The History of Synthetic Biology Living Medicines Designing Synthetic Biotics Pipeline Partner with Us Clinical Trials Our People Leadership Board of Directors Founders and Advisors Join Us Investors + Media Company Overview News News Releases In the News Events & Presentations Events Presentations Publications Stock Information Stock Quote & Chart Analyst Coverage Corporate Governance Governance Highlights Management Team Board of Directors Committee Composition Board Diversity Matrix Financials Quarterly Results Investor Resources FAQs Contact IR Email Alerts RSS Feeds Synlogic Announces SYNB1353 Achieves Proof of Mechanism for Treatment of Homocystinuria Nov 30, 2022 Supporting Materials SYNB1353 Phase 1 Top-line Results 1.4 MB Investor Resources Contact IR Investor FAQs RSS Feeds Investor Email Alerts Email
Synlogic Announces SYNB1353 Achieves Proof of Mechanism for Treatment of Homocystinuria Nov 30, 2022 Supporting Materials SYNB1353 Phase 1 Top-line Results 1.4 MB